基于稻壳灰合成和表征了基于介孔硅酸盐MCM-41 (MSNCs)的热/酸碱敏感纳米复合材料。MSNCs被温敏/酸碱敏感的Pluronic® F127和明胶所包裹，形成MSNCs@gp纳米复合材料，用于抗癌药物多柔比星(Dox)的控释携带。对MSNCs@gp-Dox在体外和体内抗肿瘤效能进行了评估。傅里叶变换红外(FTIR)光谱通过检测Si-O-Si基团确认了MSNCs@gp的硅质性质。在酸性微环境 (pH 5.4)和42 °C下，与生理条件相比，MSNCs@gp-Dox显示出明显更高的Dox释放 (47.33 %)。在模拟肿瘤环境下观察到热/酸碱敏感的药物释放 (47.33 %)。Makoid-Banakar模型在pH 7.4和37 °C下提供了最佳拟合，具有均方差为0.4352，赤池信息准则为15.00，回归系数为0.9972。细胞毒性测试表明，在各种浓度的MSNCs@gp处理下，HepG2细胞没有明显毒性，而MSNCs@gp-Dox诱导了明显的细胞凋亡。裸鼠体内研究显示，MSNCs@gp-Dox有效抑制了肝癌的生长，表明具有高度药效的药物输送系统。研究的MSNCs@gp基药物输送系统显示了对肝癌治疗的潜力，以增强治疗效果并减少副作用。版权所有 © 2023. Elsevier B.V出版。

Thermo-/pH-sensitive nanocomposites based on mesoporous silicate MCM-41 (MSNCs) derived from rice husk ash were synthesized and characterized. MSNCs were coated with thermo-/pH-sensitive Pluronic® F127 and gelatin to form MSNCs@gp nanocomposites, serving as carriers for controlled release of the anticancer drug doxorubicin (Dox). The in vitro and in vivo antitumor efficacy of MSNCs@gp-Dox against liver cancer was evaluated. Fourier-transform infrared (FTIR) spectra confirmed the silica nature of MSNCs@gp by detecting the Si-O-Si group. Under acidic microenvironments (pH 5.4) and 42 °C, MSNCs@gp-Dox exhibited significantly higher Dox release (47.33 %) compared to physiological conditions. Thermo-/pH-sensitive drug release (47.33 %) was observed in simulated tumor environments. The Makoid-Banakar model provided the best fit at pH 7.4 and 37 °C with a mean squared error of 0.4352, an Akaike Information Criterion of 15.00, and a regression coefficient of 0.9972. Cytotoxicity tests have demonstrated no significant toxicity in HepG2 cells treated with various concentrations of MSNCs@gp, while MSNCs@gp-Dox induced considerable cell apoptosis. In vivo studies in nude mice revealed effective suppression of liver cancer growth by MSNCs@gp-Dox, indicating high pharmaceutical efficacy. The investigated MSNCs@gp-based drug delivery system shows promise for liver cancer therapy, offering enhanced treatment efficiency with minimal side effects.Copyright © 2023. Published by Elsevier B.V.